Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Oragenics Enters into an Exclusive Global Licence Agreement with Inspirevax

Wednesday, March 01, 2023

Oragenics announced that the Company has entered into an exclusive global licence agreement with Inspirevax for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics’ lead intranasal COVID-19 vaccine candidate.

Under the exclusive licencing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax’s novel BDX301 intranasal mucosal adjuvant. Additionally, the agreement provides a certain period of time for the companies to expand collaboration to pursue the development of additional intranasal vaccine candidates using Inspirevax’s adjuvants.

This agreement is an important milestone in expanding development opportunities for Oragenics and for company's strategic initiatives. This collaboration with experts of Inspirevax enables to pursue the development of novel intranasal vaccine candidates.

Intranasally delivered vaccines with BDX301 adjuvant have shown encouraging results in preclinical models for COVID-19 infections. This partnership with Oragenics’ ensures for the development of a potential novel intranasal vaccine candidate in the global fight against COVID-19 and infectious disease.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024